Granules stock ends over 4% up after US subsidiary clears FDA audit

The audit is a pre-approval inspection for three of its applications filed from this facility.

Jul 22, 2021 04:07 IST India Infoline News Service

Granules India
Granules India-led, US-based wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI) had undergone a Pre-Approval Inspection (PAI) audit by the U.S. Food and Drug Administration (FDA) from 21st June 2021 to 25th June 2021.

“The observations were responded to within the stipulated time, and we are happy to inform that the FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021. This is the fifth US FDA audit for this facility” said Priyanka Chigurupati, Executive Director, GPI.

The audit is a pre-approval inspection for three of its applications filed from this facility. The FDA issued two minor observations during the audit.

On Sensex, Granules stock completed at Rs383.75 per piece up by 4.3%. 

Related Story

Open Free Demat Account (Rs699)